4//SEC Filing
DOWNEY BRUCE 4
Accession 0001179110-20-010059
CIK 0001235010other
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:10 PM ET
Size
26.0 KB
Accession
0001179110-20-010059
Insider Transaction Report
Form 4
DOWNEY BRUCE
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−17,750→ 0 totalExercise: $18.19Exp: 2021-06-14→ Common Stock (17,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−8,855→ 0 totalExercise: $22.30Exp: 2028-06-20→ Common Stock (8,855 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−17,750→ 0 totalExercise: $14.87Exp: 2022-06-13→ Common Stock (17,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−17,750→ 0 totalExercise: $14.42Exp: 2023-06-11→ Common Stock (17,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−11,000→ 0 totalExercise: $10.97Exp: 2026-06-23→ Common Stock (11,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−25,000→ 0 totalExercise: $38.09Exp: 2030-06-23→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−17,750→ 0 totalExercise: $13.16Exp: 2024-06-12→ Common Stock (17,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−11,207→ 0 totalExercise: $17.20Exp: 2027-06-20→ Common Stock (11,207 underlying) - Disposition to Issuer
Common Stock
2020-10-01−41,844→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−17,750→ 0 totalExercise: $22.18Exp: 2025-06-10→ Common Stock (17,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−25,000→ 0 totalExercise: $12.64Exp: 2029-06-19→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
- [F2]Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Documents
Issuer
MOMENTA PHARMACEUTICALS INC
CIK 0001235010
Entity typeother
Related Parties
1- filerCIK 0001237257
Filing Metadata
- Form type
- 4
- Filed
- Sep 30, 8:00 PM ET
- Accepted
- Oct 1, 5:10 PM ET
- Size
- 26.0 KB